Hikma Pharmaceuticals (LON:HIK) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,926.51 ($24.98) and traded as high as GBX 1,942 ($25.18). Hikma Pharmaceuticals shares last traded at GBX 1,920 ($24.90), with a volume of 415,904 shares trading hands.

Analysts Set New Price Targets

Separately, Berenberg Bank raised Hikma Pharmaceuticals to a “buy” rating and boosted their target price for the stock from GBX 2,100 ($27.23) to GBX 2,400 ($31.12) in a research note on Monday, September 2nd.

Hikma Pharmaceuticals Price Performance

The company has a 50 day moving average price of GBX 1,945.08 and a 200-day moving average price of GBX 1,926.51. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The company has a market cap of £4.26 billion, a price-to-earnings ratio of 2,953.85, a P/E/G ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were issued a dividend of $0.32 per share. The ex-dividend date was Thursday, August 15th. This represents a dividend yield of 1.37%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 9,538.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.